The Librarian
-
Posts
12,294 -
Joined
-
Last visited
-
Days Won
88
Content Type
Profiles
Forums
Store
World Wiki
Events
Everything posted by The Librarian
-
New Fashion: 'Synchronized Baptisms'
The Librarian replied to The Librarian's topic in Jehovah’s Witnesses's Topics
@James Thomas Rook Jr. oh my word that was funny..... and really brought me back a few decades. Thank you. -
Love Never Fails_St. Louis International Convention.mp4 Jehovah's Witnesses International Convention "Love Never Fails" St. Louis
-
10000000_184440349233108_838275694446094741_n.mp4
-
-
Welcome back! I have not experienced this. Sounds painful.
-
And the answer to your question is yes. Remember "overlapping generations"... of which there are many discussions in this club.
-
@Bubba Johnson Jr Not sure who you mean by "you".... but this is the group for JW stuff. You posted in the main section for everyone (including athiests etc...) You can also ask the @admin on his profile any questions regarding the entire site and the many different clubs (groups)
-
-
-
Congregación Arenal de México.
-
https://download-a.akamaihd.net/files/media_periodical/16/jwb_E_201908_09_r720P.mp4
-
For the first time at Nebraska Medicine, a bloodless stem cell transplant has been performed on a Jehovah's Witness.
-
"International Association of Exorcists"? Lecturing the Catholic Church on evil? You just can't make this stuff up.....
-
Erythropoietin and iron supplements have been used for 30 years to treat anemia in patients with chronic kidney disease, but erythropoiesis-stimulating agents can only be safely used to increase hemoglobin levels to 11 g per deciliter. Roxadustat, a member of a new class of drugs called hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors, stimulates erythropoiesis and regulates iron metabolism. As reported in The New England Journal of Medicine, results from two Phase 3 randomized, clinical trials in China suggest that roxadustat may be beneficial for patients with chronic kidney disease. During the 26-week trials, 154 patients with chronic kidney disease not receiving dialysis and 305 patients undergoing long-term dialysis were randomized to receive either roxadustat or epoetin alfa (or a placebo for patients not receiving dialysis). Hemoglobin levels increased and hepcidin levels decreased in both groups of patients receiving roxadustat. Furthermore, roxadustat increased transferrin levels while maintaining serum iron levels and attenuated decreases in transferrin saturation levels. However, patients taking roxadustat were more likely to have hyperkalemia and upper respiratory infections. Allowing hemoglobin levels to be normalized, roxadustat may transform the treatment of chronic kidney disease. Ongoing clinical trials are monitoring roxadustat’s use over longer periods and in other populations. References: Chen N, Hao C, Peng X, Lin H, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. The New England Journal of Medicine 2019 Chen N, Hao C, Liu BC, Lin H, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. The New England Journal of Medicine 2019 Kaplan J. Roxadustat and anemia of chronic kidney disease. The New England Journal of Medicine 2019
-
Soon we will have to ditch the business suit since it is becoming fashion relegated to lawyers, courthouses etc... The most common "business suit' now is Khakis .... I won't even mention the IT world.
-
The first time I have heard this. Interesting thought.
-
Why would someone order a bottle of Ethos water at the Starbucks counter rather than a free 20 oz glass of water?
-
Here is another version for y'all 2019 - RC Love Never Fails - Notebook.pdf
-
@BillyTheKid46 I have deleted his threatening message. @JOHN BUTLER I believe you were referring to angels doing the killing at some time in the future and not inciting others to harm anyone. Either way, both of you need to tone it down or I will block you both.
-
-
So.... what happens if your thought isn't the same as Mr. Xi?
- 3 replies
-
- 1
-
-
- xi jinping
- karl marx
- (and 5 more)
